Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized antibiotic dosing could save ICU pneumonia patients

NCT ID NCT04986254

Knowledge-focused Sponsor: The University of Queensland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at 179 ICU patients with pneumonia to figure out the best doses of common antibiotics. Researchers took blood and lung fluid samples to measure how the drugs move through the body. The goal was to create personalized dosing plans that ensure enough antibiotic reaches the infection site, which could improve treatment and fight drug resistance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
antibiotics (benzylpenicillin, ceftriaxone, meropenem, piperacillin/tazobactam)
What this could lead to
If successful, this could lead to personalized antibiotic dosing for ICU pneumonia patients, potentially improving cure rates and reducing antibiotic resistance.
What could go wrong
This was a small, early-stage study (179 participants) focused on measuring drug levels, not on patient outcomes. The proposed dosing regimens still need to be tested in larger trials to see if they actually improve survival or recovery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

179 people

The number who actually took part.

Started

Oct 2019

Finished

Jan 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A critically ill patient in the ICU who is receiving either benzylpenicillin, ceftriaxone, meropenem or piperacillin/tazobactam for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically diagnosed lung infection, who meets all the inclusion criteria and none of the exclusion criteria will be considered for study participation.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult (≥18 years old) ICU patients 2. Confirmed or suspected either community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically diagnosed lung infection 3. Patient has been prescribed or is receiving one of the study drugs (benzylpenicillin, ceftriaxone, meropenem, or piperacillin/tazobactam) for the treatment of pneumonia in the ICU 4. Patient is sedated and receiving mechanical ventilation 5. Patient has arterial line and urinary catheter in situ for blood and urine samplings 6. Informed consent to participate in the study Exclusion Criteria: 1. Suspected or known hypersensitivity towards beta-lactam antibiotics (pre- or post-enrolment) 2. Receiving renal replacement therapy (RRT) 3. Pregnant patients or lactating mothers 4. Has received study antibiotic for more than 72 hours (at time of Occasion 1) during current infective episode.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pneumonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Critical Illness pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pneumonia

Contacts and locations

Locations

  • Centre Hospitalier Universitaire de Nimes

    Nîmes, France

  • Chinese University of Hong Kong

    Hong Kong, Hong Kong

  • Royal Brisbane and Women's Hospital

    Brisbane, Australia

  • The Alfred

    Melbourne, Australia

  • University Hospital, Ghent

    Ghent, Belgium

  • University of Malaya

    Kuala Lumpur, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.